Number 6 - JUNE 2005
COLORECTAL CANCER - ADJUVANT THERAPY

Amichetti M, Lay G, Dessi M, Orru S, Farigu R, Orru P, Farci D, Melis S; Cagliari Neuro-Oncology Group. Results of whole brain radiation therapy in patients with brain metastases from colorectal carcinoma. Tumori. 2005 Mar-pr;91(2):163-7.   

Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005 May 20;23(15):3502-8.  

Motl S. Bevacizumab in combination chemotherapy for colorectal and other cancers. Am J Health Syst Pharm. 2005 May 15;62(10):1021-32. 

Fernandez-Cebrian JM, Vorwald Kuborn P, Pardo de Lama M, Sanjuanbenito Dehesa A, Nevado Santos M, Pacheco Martinez PA, Fernandez-Escudero B.  [Current status of the prognostic value of molecular markers in patients with colorectal cancer and the prediction of response to adjuvant therapy] Clin Transl Oncol. 2005 Apr;7(3):101-9. 

Aschele C, Friso ML, Pucciarelli S, Lonardi S, Sartor L, Fabris G, Urso ED, Del Bianco P, Sotti G, Lise M, Monfardini S. A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol. 2005 May 13;  

Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
J Clin Oncol. 2005 Jun 1;23(16):3706-12 

Feliu J, Escudero P, Llosa F, Bolanos M, Vicent JM, Yubero A, Sanz-Lacalle JJ, Lopez R, Lopez-Gomez L, Casado E, Gomez-Reina MJ, Gonzalez-Baron M. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol. 2005 May 1;23(13):3104-11.   

Negri FV, Wotherspoon A, Cunningham D, Norman AR, Chong G, Ross PJ. Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol. 2005 Apr 27; [ 

Schippinger W, Jagoditsch M, Sorre C, Gnant M, Steger G, Hausmaninger H, Mlineritsch B, Schaberl-Moser R, Mischinger HJ, Hofbauer F, Holzberger P, Mittlbock M, Jakesz R; Austrian Breast and Colorectal Cancer Study Group. A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer. Br J Cancer. 2005 May 9;92(9):1655-62.  

Lima AP, del Giglio A.  Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience. Eur J Cancer Care (Engl). 2005 May;14(2):151-4.  

Diaz-Gonzalez JA, Calvo FA, Cortes J, de La Mata D, Gomez-Espi M, Lozano MA, Lozano E, Serrano J, Herranz R. Preoperative chemoradiation with oral tegafur within a multidisciplinary therapeutic approach in patients with T3-4 rectal cancer. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1378-84.  

Wang LW, Yang SH, Lin JK, Lin TC, Chan WK, Chen WS, Wang HS, Jiang JK, Lee RC, Li AF, Chao Y, Chi KH, Yen SH. Pre-operative chemoradiotherapy with oral tegafur-uracil and leucovorin for rectal cancer. J Surg Oncol. 2005 Mar 15;89(4):256-63; discussion 263-4 

Chau I, Norman AR, Cunningham D, Tait D, Ross PJ, Iveson T, Hill M, Hickish T, Lofts F, Jodrell D, Webb A, Oates JR. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol. 2005 Apr;16(4):549-57.  

Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005 Mar 20;23(9):1803-10.  

Delaunoit T, Alberts SR, Sargent DJ, Green E, Goldberg RM, Krook J, Fuchs C, Ramanathan RK, Williamson SK, Morton RF, Findlay BP. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol. 2005 Mar;16(3):425-9. 

Maiello E, Gebbia V, Giuliani F, Paoletti G, Gebbia N, Borsellino N, Carteni G, Pezzella G, Manzione L, Romito S, Lopez M, Colucci G. FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol. 2005 May;16 Suppl 4:iv56-iv60.  

 Makatsoris T, Kalofonos HP, Aravantinos G, Papadimitriou C, Kastritis E, Rigatos SK, Xiros N, Petsas T, Economopoulos T, Sakadamis AK, Fountzilas G. A Phase II Study of Capecitabine Plus Oxaliplatin (XELOX): A New First-Line Option in Metastatic Colorectal Cancer. Int J Gastrointest Cancer. 2005 Apr;35(2):103-110.